391 results on '"Vrzalikova, K."'
Search Results
2. Epstein–Barr Virus and the Pathogenesis of Diffuse Large B-Cell Lymphoma
- Author
-
AM, Ross, Leahy CI, Neylon F, Steigerova J, Flodr P, Navratilova M, Urbankova H, Vrzalikova K, Mundo L, Lazzi S, Leoncini L, Pugh M, and PG, Murray
- Abstract
Epstein–Barr virus (EBV), defined as a group I carcinogen by the World Health Organization (WHO), is present in the tumour cells of patients with different forms of B-cell lymphoma, including Burkitt lymphoma, Hodgkin lymphoma, post-transplant lymphoproliferative disorders, and, most recently, diffuse large B-cell lymphoma (DLBCL). Understanding how EBV contributes to the development of these different types of B-cell lymphoma has not only provided fundamental insights into the underlying mechanisms of viral oncogenesis, but has also highlighted potential new therapeutic opportunities. In this review, we describe the effects of EBV infection in normal B-cells and we address the germinal centre model of infection and how this can lead to lymphoma in some instances. We then explore the recent reclassification of EBV+ DLBCL as an established entity in the WHO fifth edition and ICC 2022 classifications, emphasising the unique nature of this entity. To that end, we also explore the unique genetic background of this entity and briefly discuss the potential role of the tumour microenvironment in lymphomagenesis and disease progression. Despite the recent progress in elucidating the mechanisms of this malignancy, much work remains to be done to improve patient stratification, treatment strategies, and outcomes.
- Published
- 2023
- Full Text
- View/download PDF
3. The Oncogenic Lipid Sphingosine-1-Phosphate Impedes the Phagocytosis of Tumor Cells by M1 Macrophages in Diffuse Large B Cell Lymphoma.
- Author
-
Perry TA, Masand N, Vrzalikova K, Pugh M, Wei W, Hollows R, Bouchalova K, Nohtani M, Fennell E, Bouchal J, Kearns P, and Murray PG
- Abstract
Background: A total of 30-40% of diffuse large B cell lymphoma (DLBCL) patients will either not respond to the standard therapy or their disease will recur. The first-line treatment for DLBCL is rituximab and combination chemotherapy. This treatment involves the chemotherapy-induced recruitment of tumor-associated macrophages that recognize and kill rituximab-opsonized DLBCL cells. However, we lack insights into the factors responsible for the recruitment and functionality of macrophages in DLBCL tumors., Methods: We have studied the effects of the immunomodulatory lipid sphingosine-1-phosphate (S1P) on macrophage activity in DLBCL, both in vitro and in animal models., Results: We show that tumor-derived S1P mediates the chemoattraction of both monocytes and macrophages in vitro and in animal models, an effect that is dependent upon the S1P receptor S1PR1. However, S1P inhibited M1 macrophage-mediated phagocytosis of DLBCL tumor cells opsonized with the CD20 monoclonal antibodies rituximab and ofatumumab, an effect that could be reversed by an S1PR1 inhibitor., Conclusions: Our data show that S1P signaling can modulate macrophage recruitment and tumor cell killing by anti-CD20 monoclonal antibodies in DLBCL. The administration of S1PR1 inhibitors could enhance the phagocytosis of tumor cells and improve outcomes for patients.
- Published
- 2024
- Full Text
- View/download PDF
4. S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells
- Author
-
Vrzalikova, K, Ibrahim, M, Vockerodt, M, Perry, T, Margielewska, S, Lupino, L, Nagy, E, Soilleux, E, Liebelt, D, Hollows, R, Last, A, Reynolds, G, Abdullah, M, Curley, H, Care, M, Krappmann, D, Tooze, R, Allegood, J, Spiegel, S, Wei, W, Woodman, C BJ, and Murray, P G
- Published
- 2018
- Full Text
- View/download PDF
5. Correction: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells
- Author
-
Vrzalikova, K, Ibrahim, M, Vockerodt, M, Perry, T, Margielewska, S, Lupino, L, Nagy, E, Soilleux, E, Liebelt, D, Hollows, R, Last, A, Reynolds, G, Abdullah, M, Curley, H, Care, M, Krappmann, D, Tooze, R, Allegood, J, Spiegel, S, Wei, W, Woodman, C B J, and Murray, P G
- Published
- 2019
- Full Text
- View/download PDF
6. Epstein-Barr Virus and the Pathogenesis of Diffuse Large B-Cell Lymphoma.
- Author
-
Ross AM, Leahy CI, Neylon F, Steigerova J, Flodr P, Navratilova M, Urbankova H, Vrzalikova K, Mundo L, Lazzi S, Leoncini L, Pugh M, and Murray PG
- Abstract
Epstein-Barr virus (EBV), defined as a group I carcinogen by the World Health Organization (WHO), is present in the tumour cells of patients with different forms of B-cell lymphoma, including Burkitt lymphoma, Hodgkin lymphoma, post-transplant lymphoproliferative disorders, and, most recently, diffuse large B-cell lymphoma (DLBCL). Understanding how EBV contributes to the development of these different types of B-cell lymphoma has not only provided fundamental insights into the underlying mechanisms of viral oncogenesis, but has also highlighted potential new therapeutic opportunities. In this review, we describe the effects of EBV infection in normal B-cells and we address the germinal centre model of infection and how this can lead to lymphoma in some instances. We then explore the recent reclassification of EBV+ DLBCL as an established entity in the WHO fifth edition and ICC 2022 classifications, emphasising the unique nature of this entity. To that end, we also explore the unique genetic background of this entity and briefly discuss the potential role of the tumour microenvironment in lymphomagenesis and disease progression. Despite the recent progress in elucidating the mechanisms of this malignancy, much work remains to be done to improve patient stratification, treatment strategies, and outcomes.
- Published
- 2023
- Full Text
- View/download PDF
7. The H3K27me3 demethylase, KDM6B, is induced by Epstein–Barr virus and over-expressed in Hodgkin's Lymphoma
- Author
-
Anderton, J A, Bose, S, Vockerodt, M, Vrzalikova, K, Wei, W, Kuo, M, Helin, K, Christensen, J, Rowe, M, Murray, P G, and Woodman, C B
- Published
- 2011
- Full Text
- View/download PDF
8. Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma.
- Author
-
Lupino L, Perry T, Margielewska S, Hollows R, Ibrahim M, Care M, Allegood J, Tooze R, Sabbadini R, Reynolds G, Bicknell R, Rudzki Z, Lin Hock Y, Zanetto U, Wei W, Simmons W, Spiegel S, Woodman CBJ, Rowe M, Vrzalikova K, and Murray PG
- Subjects
- Animals, Cell Line, Tumor, Computational Biology methods, Disease Models, Animal, Endothelial Cells metabolism, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Lymphoma, Large B-Cell, Diffuse pathology, Lysophospholipids genetics, Mice, RNA, Messenger genetics, Sphingosine genetics, Sphingosine metabolism, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse metabolism, Lysophospholipids metabolism, Neovascularization, Pathologic genetics, Neovascularization, Pathologic metabolism, Signal Transduction, Sphingosine analogs & derivatives, Transcriptome
- Abstract
Although the over-expression of angiogenic factors is reported in diffuse large B-cell lymphoma (DLBCL), the poor response to anti-VEGF drugs observed in clinical trials suggests that angiogenesis in these tumours might be driven by VEGF-independent pathways. We show that sphingosine kinase-1 (SPHK1), which generates the potent bioactive sphingolipid sphingosine-1-phosphate (S1P), is over-expressed in DLBCL. A meta-analysis of over 2000 cases revealed that genes correlated with SPHK1 mRNA expression in DLBCL were significantly enriched for tumour angiogenesis meta-signature genes; an effect evident in both major cell of origin (COO) and stromal subtypes. Moreover, we found that S1P induces angiogenic signalling and a gene expression programme that is present within the tumour vasculature of SPHK1-expressing DLBCL. Importantly, S1PR1 functional antagonists, including Siponimod, and the S1P neutralising antibody, Sphingomab, inhibited S1P signalling in DLBCL cells in vitro. Furthermore, Siponimod, also reduced angiogenesis and tumour growth in an S1P-producing mouse model of angiogenic DLBCL. Our data define a potential role for S1P signalling in driving an angiogenic gene expression programme in the tumour vasculature of DLBCL and suggest novel opportunities to target S1P-mediated angiogenesis in patients with DLBCL.
- Published
- 2019
- Full Text
- View/download PDF
9. Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas [Tiacci and Lazzi are co-senior authors]
- Author
-
Mundo, L., Del Porro, L., Granai, M., Siciliano, M. C., Mancini, V., Santi, R., Marcar, L., Vrzalikova, K., Vergoni, F., Di Stefano, G., Schiavoni, G., Segreto, G., Onyango, N., Nyagol, J. A., Amato, T., Bellan, C., Anagnostopoulos, I., Falini, B., Leoncini, L., Tiacci, E., and Lazzi, S.
- Published
- 2020
10. Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma
- Author
-
Lupino, L, Perry, T, Margielewska, S, Hollows, R, Ibrahim, M, Care, M, Allegood, J, Tooze, R, Sabbadini, R, Reynolds, G, Bicknell, R, Rudzki, Z, Lin Hock, Y, Zanetto, U, Wei, W, Simmons, W, Spiegel, S, Woodman, CBJ, Rowe, M, Vrzalikova, K, and Murray, PG
- Subjects
Neovascularization, Pathologic ,Computational Biology ,Endothelial Cells ,S1P ,SPHK1 ,Immunohistochemistry ,Article ,Gene Expression Regulation, Neoplastic ,Disease Models, Animal ,Mice ,HUVEC ,Sphingosine ,immune system diseases ,DLBCL ,Cell Line, Tumor ,hemic and lymphatic diseases ,Animals ,Humans ,lipids (amino acids, peptides, and proteins) ,Lymphoma, Large B-Cell, Diffuse ,RNA, Messenger ,Lysophospholipids ,Transcriptome ,Signal Transduction - Abstract
Although the over-expression of angiogenic factors is reported in diffuse large B-cell lymphoma (DLBCL), the poor response to anti-VEGF drugs observed in clinical trials suggests that angiogenesis in these tumours might be driven by VEGF-independent pathways. We show that sphingosine kinase-1 (SPHK1), which generates the potent bioactive sphingolipid sphingosine-1-phosphate (S1P), is over-expressed in DLBCL. A meta-analysis of over 2000 cases revealed that genes correlated with SPHK1 mRNA expression in DLBCL were significantly enriched for tumour angiogenesis meta-signature genes; an effect evident in both major cell of origin (COO) and stromal subtypes. Moreover, we found that S1P induces angiogenic signalling and a gene expression programme that is present within the tumour vasculature of SPHK1-expressing DLBCL. Importantly, S1PR1 functional antagonists, including Siponimod, and the S1P neutralising antibody, Sphingomab, inhibited S1P signalling in DLBCL cells in vitro. Furthermore, Siponimod, also reduced angiogenesis and tumour growth in an S1P-producing mouse model of angiogenic DLBCL. Our data define a potential role for S1P signalling in driving an angiogenic gene expression programme in the tumour vasculature of DLBCL and suggest novel opportunities to target S1P-mediated angiogenesis in patients with DLBCL.
- Published
- 2019
11. Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL.
- Author
-
Nohtani M, Vrzalikova K, Ibrahim M, Powell JE, Fennell É, Morgan S, Grundy R, McCarthy K, Dewberry S, Bouchal J, Bouchalova K, Kearns P, and Murray PG
- Abstract
In this study, we have re-evaluated how EBV status influences clinical outcome. To accomplish this, we performed a literature review of all studies that have reported the effect of EBV status on patient outcome and also explored the effect of EBV positivity on outcome in a clinical trial of children with cHL from the UK. Our literature review revealed that almost all studies of older adults/elderly patients have reported an adverse effect of an EBV-positive status on outcome. In younger adults with cHL, EBV-positive status was either associated with a moderate beneficial effect or no effect, and the results in children and adolescents were conflicting. Our own analysis of a series of 166 children with cHL revealed no difference in overall survival between EBV-positive and EBV-negative groups ( p = 0.942, log rank test). However, EBV-positive subjects had significantly longer event-free survival ( p = 0.0026). Positive latent membrane protein 1 (LMP1) status was associated with a significantly lower risk of treatment failure in a Cox regression model (HR = 0.21, p = 0.005). In models that controlled for age, gender, and stage, EBV status had a similar effect size and statistical significance. This study highlights the age-related impact of EBV status on outcome in cHL patients and suggests different pathogenic effects of EBV at different stages of life.
- Published
- 2022
- Full Text
- View/download PDF
12. T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice
- Author
-
Oldreive, C.E., Skowronska, A., Davies, N.J., Parry, H., Agathanggelou, A., Krysov, S., Packham, G., Rudzki, Z., Cronin, L., Vrzalikova, K., Murray, P., Odintsova, E., Pratt, G., Taylor, A.M., Moss, P., and Stankovic, T.
- Subjects
Cytotoxicity, Immunologic ,Time Factors ,Cell Survival ,lcsh:Medicine ,Mice, SCID ,CD8-Positive T-Lymphocytes ,Lymphocyte Activation ,Lymphocyte Depletion ,Mouse model ,Immunocompromised Host ,Lymphocytes, Tumor-Infiltrating ,Mice, Inbred NOD ,T-Lymphocyte Subsets ,hemic and lymphatic diseases ,lcsh:Pathology ,Tumor Microenvironment ,Animals ,Humans ,Cells, Cultured ,Cell Proliferation ,lcsh:R ,Graft Survival ,Leukemia, Lymphocytic, Chronic, B-Cell ,Coculture Techniques ,Phenotype ,T-cell depletion ,Heterografts ,CLL ,Neoplasm Transplantation ,Spleen ,lcsh:RB1-214 ,Research Article - Abstract
Chronic lymphocytic leukaemia (CLL) cells require microenvironmental support for their proliferation. This can be recapitulated in highly immunocompromised hosts in the presence of T cells and other supporting cells. Current primary CLL xenograft models suffer from limited duration of tumour cell engraftment coupled with gradual T-cell outgrowth. Thus, a greater understanding of the interaction between CLL and T cells could improve their utility. In this study, using two distinct mouse xenograft models, we investigated whether xenografts recapitulate CLL biology, including natural environmental interactions with B-cell receptors and T cells, and whether manipulation of autologous T cells can expand the duration of CLL engraftment. We observed that primary CLL xenografts recapitulated both the tumour phenotype and T-cell repertoire observed in patients and that engraftment was significantly shorter for progressive tumours. A reduction in the number of patient T cells that were injected into the mice to 2-5% of the initial number or specific depletion of CD8+ cells extended the limited xenograft duration of progressive cases to that characteristic of indolent disease. We conclude that manipulation of T cells can enhance current CLL xenograft models and thus expand their utility for investigation of tumour biology and pre-clinical drug assessment., Summary: Manipulation of T cells can enhance current CLL xenograft models, expanding their utility for investigation of tumour biology and pre-clinical drug assessment.
- Published
- 2015
13. S1PR1 drives a feed forward signalling loop to regulate BATF3 and the transcriptional programme of hodgkin lymphoma cells
- Author
-
Vrzalikova, K., Ibrahim, M., Vockerodt, M., Perry, T., Margielewska, S., Lupino, L., Nagy, E., Soilleux, E., Liebelt, D., Hollows, R., Last, A., Reynolds, G., Abdullah, M., Curley, H., Care, M., Krappmann, D., Tooze, R., Allegood, J., Spiegel, S., Wei, W., Woodman, C.B.J., and Murray, P.G.
- Abstract
The Hodgkin/Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (HL) are characterised by the aberrant activation of multiple signalling pathways. Here we show that a subset of HL displays altered expression of sphingosine-1-phosphate (S1P) receptors (S1PR). S1P activates phosphatidylinositide 3-kinase (PI3-K) in these cells that is mediated by the increased expression of S1PR1 and the decreased expression of S1PR2. We also showed that genes regulated by PI3-K signalling pathway in HL cell lines significantly overlap with the transcriptional programme of primary HRS cells. Genes up-regulated by the PI3-K pathway included the basic leucine zipper transcription factor, ATF-like 3 (BATF3), which is normally associated with the development of dendritic cells. Immunohistochemistry confirmed that BATF3 was expressed in HRS cells of most HL cases. In contrast, in normal lymphoid tissues, BATF3 expression was confined to a small fraction of CD30-positive immunoblasts. Knockdown of BATF3 in HL cell lines revealed that BATF3 contributed to the transcriptional programme of primary HRS cells, including the upregulation of S1PR1. Our data suggest that disruption of this potentially oncogenic feed-forward S1P signalling loop could provide novel therapeutic opportunities for patients with HL.Leukemia accepted article preview online, 07 September 2017. doi:10.1038/leu.2017.275.
- Published
- 2017
14. S1PR1 drives a feedforward signaling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells
- Author
-
Vrzalikova, K., Ibrahim, M., Vockerodt, M., Perry, T., Margielewska, S., Lupino, L., Nagy, E., Soilleux, E., Liebelt, D., Hollows, R., Last, A., Reynolds, G., Abdullah, M., Curley, H., Care, M., Krappmann, D., Tooze, R., Allegood, J., Spiegel, S., Wei, W., Woodman, C. B. J., Murray, P. G., Vrzalikova, K., Ibrahim, M., Vockerodt, M., Perry, T., Margielewska, S., Lupino, L., Nagy, E., Soilleux, E., Liebelt, D., Hollows, R., Last, A., Reynolds, G., Abdullah, M., Curley, H., Care, M., Krappmann, D., Tooze, R., Allegood, J., Spiegel, S., Wei, W., Woodman, C. B. J., and Murray, P. G.
- Abstract
The Hodgkin/Reed–Sternberg cells of classical Hodgkin lymphoma (HL) are characterised by the aberrant activation of multiple signalling pathways. Here we show that a subset of HL displays altered expression of sphingosine-1-phosphate (S1P) receptors (S1PR)s. S1P activates phosphatidylinositide 3-kinase (PI3-K) in these cells that is mediated by the increased expression of S1PR1 and the decreased expression of S1PR2. We also showed that genes regulated by the PI3-K signalling pathway in HL cell lines significantly overlap with the transcriptional programme of primary HRS cells. Genes upregulated by the PI3-K pathway included the basic leucine zipper transcription factor, ATF-like 3 (BATF3), which is normally associated with the development of dendritic cells. Immunohistochemistry confirmed that BATF3 was expressed in HRS cells of most HL cases. In contrast, in normal lymphoid tissues, BATF3 expression was confined to a small fraction of CD30-positive immunoblasts. Knockdown of BATF3 in HL cell lines revealed that BATF3 contributed to the transcriptional programme of primary HRS cells, including the upregulation of S1PR1. Our data suggest that disruption of this potentially oncogenic feedforward S1P signalling loop could provide novel therapeutic opportunities for patients with HL.
- Published
- 2017
15. S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells
- Author
-
Vrzalikova, K, primary, Ibrahim, M, additional, Vockerodt, M, additional, Perry, T, additional, Margielewska, S, additional, Lupino, L, additional, Nagy, E, additional, Soilleux, E, additional, Liebelt, D, additional, Hollows, R, additional, Last, A, additional, Reynolds, G, additional, Abdullah, M, additional, Curley, H, additional, Care, M, additional, Krappmann, D, additional, Tooze, R, additional, Allegood, J, additional, Spiegel, S, additional, Wei, W, additional, Woodman, C B J, additional, and Murray, P G, additional
- Published
- 2017
- Full Text
- View/download PDF
16. Correction: Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas.
- Author
-
Mundo L, Del Porro L, Granai M, Siciliano MC, Mancini V, Santi R, Marcar L, Vrzalikova K, Vergoni F, Di Stefano G, Schiavoni G, Segreto G, Onyango N, Nyagol JA, Amato T, Bellan C, Anagnostopoulos I, Falini B, Leoncini L, Tiacci E, and Lazzi S
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
- Full Text
- View/download PDF
17. Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas.
- Author
-
Mundo L, Del Porro L, Granai M, Siciliano MC, Mancini V, Santi R, Marcar L, Vrzalikova K, Vergoni F, Di Stefano G, Schiavoni G, Segreto G, Onyango N, Nyagol JA, Amato T, Bellan C, Anagnostopoulos I, Falini B, Leoncini L, Tiacci E, and Lazzi S
- Subjects
- Epstein-Barr Virus Infections diagnosis, Hodgkin Disease diagnosis, Humans, Italy, Lymphoma, Non-Hodgkin diagnosis, Molecular Diagnostic Techniques, U937 Cells, Viral Load, Epstein-Barr Virus Infections virology, Epstein-Barr Virus Nuclear Antigens genetics, Herpesvirus 4, Human genetics, Hodgkin Disease virology, Lymphoma, Non-Hodgkin virology, RNA, Messenger genetics, RNA, Viral genetics
- Abstract
The Epstein-Barr virus (EBV) is linked to various B-cell lymphomas, including Burkitt lymphoma (BL), classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) at frequencies ranging, by routine techniques, from 5 to 10% of cases in DLBCL to >95% in endemic BL. Using higher-sensitivity methods, we recently detected EBV traces in a few EBV-negative BL cases, possibly suggesting a "hit-and-run" mechanism. Here, we used routine and higher-sensitivity methods (qPCR and ddPCR for conserved EBV genomic regions and miRNAs on microdissected tumor cells; EBNA1 mRNA In situ detection by RNAscope) to assess EBV infection in a larger lymphoma cohort [19 BL, 34 DLBCL, 44 cHL, 50 follicular lymphomas (FL), 10 T-lymphoblastic lymphomas (T-LL), 20 hairy cell leukemias (HCL), 10 mantle cell lymphomas (MCL)], as well as in several lymphoma cell lines (9 cHL and 6 BL). qPCR, ddPCR, and RNAscope consistently documented the presence of multiple EBV nucleic acids in rare tumor cells of several cases EBV-negative by conventional methods that all belonged to lymphoma entities clearly related to EBV (BL, 6/9 cases; cHL, 16/32 cases; DLBCL, 11/30 cases), in contrast to fewer cases (3/47 cases) of FL (where the role of EBV is more elusive) and no cases (0/40) of control lymphomas unrelated to EBV (HCL, T-LL, MCL). Similarly, we revealed traces of EBV infection in 4/5 BL and 6/7 HL cell lines otherwise conventionally classified as EBV negative. Interestingly, additional EBV-positive cases (1 DLBCL, 2 cHL) relapsed as EBV-negative by routine methods while showing EBNA1 expression in rare tumor cells by RNAscope. The relapse specimens were clonally identical to their onset biopsies, indicating that the lymphoma clone can largely loose the EBV genome over time but traces of EBV infection are still detectable by high-sensitivity methods. We suggest EBV may contribute to lymphoma pathogenesis more widely than currently acknowledged.
- Published
- 2020
- Full Text
- View/download PDF
18. Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma.
- Author
-
Vockerodt M, Vrzalikova K, Ibrahim M, Nagy E, Margielewska S, Hollows R, Lupino L, Tooze R, Care M, Simmons W, Schrader A, Perry T, Abdullah M, Foster S, Reynolds G, Dowell A, Rudzki Z, Krappmann D, Kube D, Woodman C, Wei W, Taylor G, and Murray PG
- Subjects
- CD40 Antigens genetics, CD40 Antigens metabolism, Cell Line, Tumor, Cell Transformation, Viral, Databases, Genetic, Epstein-Barr Virus Infections mortality, Gene Expression Regulation, Neoplastic, Herpesvirus 4, Human genetics, Host-Pathogen Interactions, Humans, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse mortality, Lymphoma, Large B-Cell, Diffuse virology, Phosphatidylinositol 3-Kinase metabolism, Prognosis, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction, Sphingosine-1-Phosphate Receptors genetics, Viral Matrix Proteins genetics, Epstein-Barr Virus Infections virology, Herpesvirus 4, Human metabolism, Lymphoma, Large B-Cell, Diffuse metabolism, Sphingosine-1-Phosphate Receptors metabolism, Viral Matrix Proteins metabolism
- Abstract
The Epstein-Barr virus (EBV) is found almost exclusively in the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), yet its contribution to this tumour remains poorly understood. We have focused on the EBV-encoded latent membrane protein-1 (LMP1), a constitutively activated CD40 homologue expressed in almost all EBV-positive DLBCLs and which can disrupt germinal centre (GC) formation and drive lymphomagenesis in mice. Comparison of the transcriptional changes that follow LMP1 expression with those that follow transient CD40 signalling in human GC B cells enabled us to define pathogenic targets of LMP1 aberrantly expressed in ABC-DLBCL. These included the down-regulation of S1PR2, a sphingosine-1-phosphate (S1P) receptor that is transcriptionally down-regulated in ABC-DLBCL, and when genetically ablated leads to DLBCL in mice. Consistent with this, we found that LMP1-expressing primary ABC-DLBCLs were significantly more likely to lack S1PR2 expression than were LMP1-negative tumours. Furthermore, we showed that the down-regulation of S1PR2 by LMP1 drives a signalling loop leading to constitutive activation of the phosphatidylinositol-3-kinase (PI3-K) pathway. Finally, core LMP1-PI3-K targets were enriched for lymphoma-related transcription factors and genes associated with shorter overall survival in patients with ABC-DLBCL. Our data identify a novel function for LMP1 in aggressive DLBCL. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd., (Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
19. Diffuse large B-cell lymphoma: The history, current view and new perspectives
- Author
-
FLODR, P., primary, LATALOVA, P., additional, TICHY, M., additional, KUBOVA, Z., additional, PAPAJIK, T., additional, SVACHOVA, M., additional, VRZALIKOVA, K., additional, RADOVA, L., additional, JAROSOVA, M., additional, and MURRAY, P., additional
- Published
- 2014
- Full Text
- View/download PDF
20. The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation.
- Author
-
Knoblich K, Cruz Migoni S, Siew SM, Jinks E, Kaul B, Jeffery HC, Baker AT, Suliman M, Vrzalikova K, Mehenna H, Murray PG, Barone F, Oo YH, Newsome PN, Hirschfield G, Kelly D, Lee SP, Parekkadan B, Turley SJ, and Fletcher AL
- Subjects
- Adult, Cell Proliferation, Child, Fibroblasts cytology, Humans, Immunologic Memory, Phenotype, Cell Differentiation immunology, Cellular Microenvironment, Lymph Nodes immunology, Lymphocyte Activation immunology, T-Lymphocytes cytology
- Abstract
The microenvironment of lymphoid organs can aid healthy immune function through provision of both structural and molecular support. In mice, fibroblastic reticular cells (FRCs) create an essential T-cell support structure within lymph nodes, while human FRCs are largely unstudied. Here, we show that FRCs create a regulatory checkpoint in human peripheral T-cell activation through 4 mechanisms simultaneously utilised. Human tonsil and lymph node-derived FRCs constrained the proliferation of both naïve and pre-activated T cells, skewing their differentiation away from a central memory T-cell phenotype. FRCs acted unilaterally without requiring T-cell feedback, imposing suppression via indoleamine-2,3-dioxygenase, adenosine 2A Receptor, prostaglandin E2, and transforming growth factor beta receptor (TGFβR). Each mechanistic pathway was druggable, and a cocktail of inhibitors, targeting all 4 mechanisms, entirely reversed the suppressive effect of FRCs. T cells were not permanently anergised by FRCs, and studies using chimeric antigen receptor (CAR) T cells showed that immunotherapeutic T cells retained effector functions in the presence of FRCs. Since mice were not suitable as a proof-of-concept model, we instead developed a novel human tissue-based in situ assay. Human T cells stimulated using standard methods within fresh tonsil slices did not proliferate except in the presence of inhibitors described above. Collectively, we define a 4-part molecular mechanism by which FRCs regulate the T-cell response to strongly activating events in secondary lymphoid organs while permitting activated and CAR T cells to utilise effector functions. Our results define 4 feasible strategies, used alone or in combinations, to boost primary T-cell responses to infection or cancer by pharmacologically targeting FRCs., Competing Interests: I have read the journal's policy, and the authors of this manuscript have the following competing interests: S. P. Lee is listed as an inventor on the following patent application/patent families regarding development of CLEC14A CAR T cells: PCT/GB2010/001689 (published as WO2011/027132), PCT/GB2016/050134 (published as WO2016/116760), PCT/GB2017/050686, and PCT/GB2017/050689.
- Published
- 2018
- Full Text
- View/download PDF
21. Co-Expression of the Epstein-Barr Virus-Encoded Latent Membrane Proteins and the Pathogenesis of Classic Hodgkin Lymphoma.
- Author
-
Vrzalikova K, Ibrahim M, Nagy E, Vockerodt M, Perry T, Wei W, Woodman C, and Murray P
- Abstract
The Epstein-Barr virus (EBV) is present in the tumour cells of a subset of patients with classic Hodgkin lymphoma (cHL), yet the contribution of the virus to the pathogenesis of these tumours remains only poorly understood. The EBV genome in virus-associated cHL expresses a limited subset of genes, restricted to the non-coding Epstein-Barr virus-encoded RNAs (EBERs) and viral miRNA, as well as only three virus proteins; the Epstein-Barr virus nuclear antigen-1 (EBNA1), and the two latent membrane proteins, known as LMP1 and LMP2, the latter of which has two isoforms, LMP2A and LMP2B. LMP1 and LMP2A are of particular interest because they are co-expressed in tumour cells and can activate cellular signalling pathways, driving aberrant cellular transcription in infected B cells to promote lymphomagenesis. This article seeks to bring together the results of recent studies of the latent membrane proteins in different B cell systems, including experiments in animal models as well as a re-analysis of our own transcriptional data. In doing so, we summarise the potentially co-operative and antagonistic effects of the LMPs that are relevant to B cell lymphomagenesis.
- Published
- 2018
- Full Text
- View/download PDF
22. Contribution of Epstein⁻Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma.
- Author
-
Vrzalikova K, Sunmonu T, Reynolds G, and Murray P
- Abstract
Pathogenic viruses have evolved to manipulate the host cell utilising a variety of strategies including expression of viral proteins to hijack or mimic the activity of cellular functions. DNA tumour viruses often establish latent infection in which no new virions are produced, characterized by the expression of a restricted repertoire of so-called latent viral genes. These latent genes serve to remodel cellular functions to ensure survival of the virus within host cells, often for the lifetime of the infected individual. However, under certain circumstances, virus infection may contribute to transformation of the host cell; this event is not a usual outcome of infection. Here, we review how the Epstein⁻Barr virus (EBV), the prototypic oncogenic human virus, modulates host cell functions, with a focus on the role of the EBV latent genes in classical Hodgkin lymphoma.
- Published
- 2018
- Full Text
- View/download PDF
23. Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.
- Author
-
Alexander LMM, Watters J, Reusch JA, Maurin M, Nepon-Sixt BS, Vrzalikova K, Alexandrow MG, Murray PG, and Wright KL
- Subjects
- Cell Division genetics, Cell Survival genetics, Cell Survival immunology, DNA Replication genetics, DNA Replication immunology, Humans, Jurkat Cells, RNA Polymerase II genetics, RNA Polymerase II immunology, Transcriptional Elongation Factors genetics, B-Lymphocytes immunology, Cell Division immunology, Gene Expression Regulation immunology, Transcriptional Elongation Factors immunology
- Abstract
B cell activation is dependent on a large increase in transcriptional output followed by focused expression on secreted immunoglobulin as the cell transitions to an antibody producing plasma cell. The rapid transcriptional induction is facilitated by the release of poised RNA pol II into productive elongation through assembly of the super elongation complex (SEC). We report that a SEC component, the Eleven -nineteen Lysine-rich leukemia (ELL) family member 3 (ELL3) is dynamically up-regulated in mature and activated human B cells followed by suppression as B cells transition to plasma cells in part mediated by the transcription repressor PRDM1. Burkitt's lymphoma and a sub-set of Diffuse Large B cell lymphoma cell lines abundantly express ELL3. Depletion of ELL3 in the germinal center derived lymphomas results in severe disruption of DNA replication and cell division along with increased DNA damage and cell death. This restricted utilization and survival dependence reveal a key step in B cell activation and indicate a potential therapeutic target against B cell lymphoma's with a germinal center origin., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
24. Data supporting the functional role of Eleven-nineteen Lysine-rich Leukemia 3 (ELL3) in B cell lymphoma cell line cells.
- Author
-
Alexander LMM, Watters J, Reusch JA, Maurin M, Nepon-Sixt BS, Vrzalikova K, Alexandrow MG, Murray PG, and Wright KL
- Abstract
The data presented here are related to the research article entitled "Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival" (Alexander et al., 2017) [1]. The cited research article characterizes Eleven-nineteen Lysine-rich Leukemia 3 (ELL3) expression in the B cell compartment and functional dependence in B lymphoma cell lines. This data report describes the mRNA expression pattern in a panel of cell lines representing the B cell compartment, supplementing the protein expression data presented in the associated research report. In addition, a reanalysis is presented of publicly available mRNA expression data from primary murine B cells to reveal dynamic regulation of the ELL family members post LPS stimulation (Barwick et al., 2016) [2]. The effect of ELL3 depletion on cell morphology, latent Epstein Barr Virus (EBV) lytic replication and differentiation markers in a Burkitt's lymphoma (BL) cell line cells are presented.
- Published
- 2017
- Full Text
- View/download PDF
25. Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma.
- Author
-
Yap LF, Velapasamy S, Lee HM, Thavaraj S, Rajadurai P, Wei W, Vrzalikova K, Ibrahim MH, Khoo AS, Tsao SW, Paterson IC, Taylor GS, Dawson CW, and Murray PG
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma physiopathology, Carcinoma, Cell Line, Tumor, Cell Movement physiology, Herpesvirus 4, Human physiology, Humans, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms pathology, Phosphoric Diester Hydrolases physiology, Receptors, Lysophosphatidic Acid genetics, T-Lymphocytes, Cytotoxic pathology, Viral Matrix Proteins physiology, Down-Regulation physiology, Epstein-Barr Virus Infections physiopathology, Gene Expression Regulation, Neoplastic physiology, Lysophospholipids physiology, Nasopharyngeal Neoplasms physiopathology, Receptors, Lysophosphatidic Acid physiology, Signal Transduction physiology
- Abstract
Undifferentiated nasopharyngeal carcinoma (NPC) is a highly metastatic disease that is consistently associated with Epstein-Barr virus (EBV) infection. In this study, we have investigated the contribution of lysophosphatidic acid (LPA) signalling to the pathogenesis of NPC. Here we demonstrate two distinct functional roles for LPA in NPC. First, we show that LPA enhances the migration of NPC cells and second, that it can inhibit the activity of EBV-specific cytotoxic T cells. Focusing on the first of these phenotypes, we show that one of the LPA receptors, LPA receptor 5 (LPAR5), is down-regulated in primary NPC tissues and that this down-regulation promotes the LPA-induced migration of NPC cell lines. Furthermore, we found that EBV infection or ectopic expression of the EBV-encoded LMP2A was sufficient to down-regulate LPAR5 in NPC cell lines. Our data point to a central role for EBV in mediating the oncogenic effects of LPA in NPC and identify LPA signalling as a potential therapeutic target in this disease., (Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
26. The Epstein-Barr virus and the pathogenesis of lymphoma.
- Author
-
Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, and Murray PG
- Subjects
- Animals, Biopsy, Epstein-Barr Virus Infections complications, Epstein-Barr Virus Infections immunology, Epstein-Barr Virus Infections pathology, Herpesvirus 4, Human immunology, Host-Pathogen Interactions, Humans, Lymphoma immunology, Lymphoma pathology, Pathology, Molecular methods, Predictive Value of Tests, Prognosis, Risk Factors, Virology methods, Virulence, Epstein-Barr Virus Infections virology, Herpesvirus 4, Human pathogenicity, Lymphoma virology
- Abstract
Since the discovery in 1964 of the Epstein-Barr virus (EBV) in African Burkitt lymphoma, this virus has been associated with a remarkably diverse range of cancer types. Because EBV persists in the B cells of the asymptomatic host, it can easily be envisaged how it contributes to the development of B-cell lymphomas. However, EBV is also found in other cancers, including T-cell/natural killer cell lymphomas and several epithelial malignancies. Explaining the aetiological role of EBV is challenging, partly because the virus probably contributes differently to each tumour and partly because the available disease models cannot adequately recapitulate the subtle variations in the virus-host balance that exist between the different EBV-associated cancers. A further challenge is to identify the co-factors involved; because most persistently infected individuals will never develop an EBV-associated cancer, the virus cannot be working alone. This article will review what is known about the contribution of EBV to lymphoma development., (Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
27. Epstein-Barr virus, the germinal centre and the development of Hodgkin's lymphoma.
- Author
-
Mohamed G, Vrzalikova K, Cader FZ, Vockerodt M, Nagy E, Flodr P, Yap LF, Diepstra A, Kluin PM, Rosati S, and Murray P
- Subjects
- Adult, B-Lymphocytes immunology, Cell Differentiation immunology, Epstein-Barr Virus Infections virology, Female, Hodgkin Disease immunology, Humans, Male, Middle Aged, Pseudolymphoma virology, Receptors, Antigen, B-Cell immunology, Viral Matrix Proteins, Virus Replication immunology, Young Adult, B-Lymphocytes virology, Germinal Center immunology, Germinal Center virology, Herpesvirus 4, Human immunology, Hodgkin Disease virology
- Abstract
The relationship between Epstein-Barr virus (EBV) and the germinal centre (GC) of the asymptomatic host remains an enigma. The occasional appearance of EBV-positive germinal centres in some patients, particularly those with a history of immunosuppression, suggests that EBV numbers in the GC are subject to immune control. The relationship, if any, between lymphoid hyperplasia with EBV-positive germinal centres and subsequent or concurrent lymphomagenesis remains to be clarified. As far as the development of EBV-associated Hodgkin's lymphoma is concerned, the suppression of virus replication, mediated by LMP1 on the one hand, and the loss of B-cell receptor signalling on the other, appears to be an important pathogenic mechanism. A further important emerging concept is that alterations in the microenvironment of the EBV-infected B-cell may be important for lymphomagenesis., (© 2014 The Authors.)
- Published
- 2014
- Full Text
- View/download PDF
28. Hypomethylation and Over-Expression of the Beta Isoform of BLIMP1 is Induced by Epstein-Barr Virus Infection of B Cells; Potential Implications for the Pathogenesis of EBV-Associated Lymphomas.
- Author
-
Vrzalikova K, Leonard S, Fan Y, Bell A, Vockerodt M, Flodr P, Wright KL, Rowe M, Tao Q, and Murray PG
- Abstract
B-lymphocyte-induced maturation protein 1 (BLIMP1) exists as two major isoforms, α and β, which arise from alternate promoters. Inactivation of the full length BLIMP1α isoform is thought to contribute to B cell lymphomagenesis by blocking post-germinal centre (GC) B cell differentiation. In contrast, the shorter β isoform is functionally impaired and over-expressed in several haematological malignancies, including diffuse large B cell lymphomas (DLBCL). We have studied the influence on BLIMP1β expression of the Epstein-Barr virus (EBV), a human herpesvirus that is implicated in the pathogenesis of several GC-derived lymphomas, including a subset of DLBCL and Hodgkin's lymphoma (HL). We show that BLIMP1β expression is increased following the EBV infection of normal human tonsillar GC B cells. We also show that this change in expression is accompanied by hypomethylation of the BLIMP1β-specific promoter. Furthermore, we confirmed previous reports that the BLIMP1β promoter is hypomethylated in DLBCL cell lines and show for the first time that BLIMP1β is hypomethylated in the Hodgkin/Reed-Sternberg (HRS) cells of HL. Our results provide evidence in support of a role for BLIMP1β in the pathogenesis of EBV-associated B cell lymphomas.
- Published
- 2012
- Full Text
- View/download PDF
29. BLIMP1α, the master regulator of plasma cell differentiation is a tumor supressor gene in B cell lymphomas.
- Author
-
Vrzalikova K, Woodman CB, and Murray PG
- Subjects
- Animals, Down-Regulation, Gene Expression Regulation, Neoplastic, Germinal Center physiology, Herpesvirus 4, Human physiology, Humans, Immunoglobulins biosynthesis, Lymphoma, B-Cell virology, Positive Regulatory Domain I-Binding Factor 1, Repressor Proteins physiology, Cell Differentiation genetics, Genes, Tumor Suppressor physiology, Lymphoma, B-Cell genetics, Plasma Cells physiology, Repressor Proteins genetics
- Abstract
Aims: The aim of this review was to summarize recent knowledge of the structure and function of a transcriptional repressor, B lymphocyte induced maturation protein 1 (BLIMP1) and its participation in the pathogenesis of B lymphomas., Methods and Results: This review summarizes the structure and function of BLIMP1, its major target genes and its role as a tumour suppressor in B cell lymphomas. We review our recent data implicating the loss of BLIMP1α as an important step in the pathogenesis of the Epstein-Barr virus (EBV) associated B cell lymphomas., Conclusions: BLIMP1 is a transcriptional repressor essential for the differentiation of germinal centre (GC) B cells to plasma cells. The loss of BLIMP1 in GC B cells could contribute to the pathogenesis of EBV-associated lymphomas by preventing plasma cell differentiation and viral replication.
- Published
- 2012
- Full Text
- View/download PDF
30. Bfl-1 is a crucial pro-survival nuclear factor-κB target gene in Hodgkin/Reed-Sternberg cells.
- Author
-
Loughran ST, Campion EM, D'Souza BN, Smith SM, Vrzalikova K, Wen K, Murray PG, and Walls D
- Subjects
- Apoptosis drug effects, Cell Line, Tumor, Gene Knockdown Techniques, Hodgkin Disease pathology, Humans, Minor Histocompatibility Antigens, NF-kappa B antagonists & inhibitors, Proto-Oncogene Proteins c-bcl-2 metabolism, Hodgkin Disease genetics, NF-kappa B pharmacology, Proto-Oncogene Proteins c-bcl-2 genetics, Reed-Sternberg Cells metabolism
- Abstract
Hodgkin/Reed-Sternberg (H/RS) cells are believed to represent clonal progeny of Germinal Centre B cells that have escaped negative selection by evading apoptosis. Aberrant constitutive activity of the transcription factor NF-κB plays a key role in the pathogenesis of Hodgkin's Lymphoma (HL), conferring a survival advantage on H/RS cells. Bfl-1 is a pro-survival NF-κB target gene from the Bcl-2 family of apoptosis-regulating proteins. Here, we report that bfl-1 (also known as A1 or GRS) is frequently expressed in primary H/RS cells from HL tumor biopsies and that elevated bfl-1 expression is a feature of H/RS derived cell lines. We show that bfl-1 is an NF-κB target gene in this cell context and that this regulation is effected through a p65-binding DNA element located in its promoter. We demonstrate that ectopic Bfl-1 can rescue cultured H/RS cells from apoptosis induced by pharmacological inhibitors of NF-κB, and that knockdown of bfl-1 potentiates the pro-apoptotic effect of these agents. These findings are the first indication that Bfl-1 plays a crucial role in setting the elevated threshold of resistance of this malignant cell type to apoptosis., (Copyright © 2011 UICC.)
- Published
- 2011
- Full Text
- View/download PDF
31. Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas.
- Author
-
Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W, Schrader A, Wright KL, Kube D, Rowe M, Woodman CB, and Murray PG
- Subjects
- B-Lymphocytes metabolism, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Blotting, Western, Cell Transformation, Viral, Cells, Cultured, Child, Epstein-Barr Virus Infections complications, Epstein-Barr Virus Infections genetics, Epstein-Barr Virus Infections virology, Gene Expression Profiling, Germinal Center, Humans, Immunoenzyme Techniques, Lymphoma, B-Cell pathology, Oligonucleotide Array Sequence Analysis, Palatine Tonsil cytology, Palatine Tonsil metabolism, Plasma Cells metabolism, Positive Regulatory Domain I-Binding Factor 1, RNA, Messenger genetics, Repressor Proteins genetics, Reverse Transcriptase Polymerase Chain Reaction, Viral Matrix Proteins genetics, Virus Latency, Virus Replication, B-Lymphocytes virology, Cell Differentiation, Herpesvirus 4, Human physiology, Lymphoma, B-Cell etiology, Plasma Cells pathology, Repressor Proteins metabolism, Viral Matrix Proteins metabolism
- Abstract
An important pathogenic event in Epstein-Barr virus (EBV)-associated lymphomas is the suppression of virus replication, which would otherwise lead to cell death. Because virus replication in B cells is intimately linked to their differentiation toward plasma cells, we asked whether the physiologic signals that drive normal B-cell differentiation are absent in EBV-transformed cells. We focused on BLIMP1α, a transcription factor that is required for plasma cell differentiation and that is inactivated in diffuse large B-cell lymphomas. We show that BLIMP1α expression is down-regulated after EBV infection of primary germinal center B cells and that the EBV oncogene, latent membrane protein-1 (LMP-1), is alone capable of inducing this down-regulation in these cells. Furthermore, the down-regulation of BLIMP1α by LMP-1 was accompanied by a partial disruption of the BLIMP1α transcriptional program, including the aberrant induction of MYC, the repression of which is required for terminal differentiation. Finally, we show that the ectopic expression of BLIMP1α in EBV-transformed cells can induce the viral lytic cycle. Our results suggest that LMP-1 expression in progenitor germinal center B cells could contribute to the pathogenesis of EBV-associated lymphomas by down-regulating BLIMP1α, in turn preventing plasma cell differentiation and induction of the viral lytic cycle.
- Published
- 2011
- Full Text
- View/download PDF
32. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study.
- Author
-
Vrzalikova K, Skarda J, Ehrmann J, Murray PG, Fridman E, Kopolovic J, Knizetova P, Hajduch M, Klein J, Kolek V, Radova L, and Kolar Z
- Subjects
- Carcinoma, Non-Small-Cell Lung pathology, Female, Gene Expression Profiling, Humans, Immunohistochemistry, Lung Neoplasms pathology, Male, Neoplasm Staging, Nuclear Proteins genetics, Polycomb Repressive Complex 1, Prognosis, Protein Array Analysis, Proto-Oncogene Proteins genetics, Repressor Proteins genetics, Tissue Array Analysis, Carcinoma, Non-Small-Cell Lung metabolism, Lung Neoplasms metabolism, Nuclear Proteins metabolism, Proto-Oncogene Proteins metabolism, Repressor Proteins metabolism
- Abstract
Purpose: Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes., Methods: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS., Results: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05)., Conclusions: Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.
- Published
- 2008
- Full Text
- View/download PDF
33. Expression of STATs and their inhibitors SOCS and PIAS in brain tumors. In vitro and in vivo study.
- Author
-
Ehrmann J, Strakova N, Vrzalikova K, Hezova R, and Kolar Z
- Subjects
- Cell Line, Tumor, Gene Expression, Humans, Molecular Chaperones metabolism, Phosphorylation, STAT Transcription Factors antagonists & inhibitors, STAT3 Transcription Factor metabolism, Signal Transduction, Suppressor of Cytokine Signaling 3 Protein, Transcriptional Activation, Brain Neoplasms drug therapy, Brain Neoplasms metabolism, Glioblastoma drug therapy, Glioblastoma metabolism, PPAR gamma antagonists & inhibitors, Protein Inhibitors of Activated STAT metabolism, STAT Transcription Factors metabolism, Small Ubiquitin-Related Modifier Proteins metabolism, Suppressor of Cytokine Signaling Proteins metabolism, Thiazolidinediones therapeutic use
- Abstract
Proteins of STAT family belongs to the transcription factors. Through their binding to the DNA specific sites and consequent regulation of transcription of various genes, these signaling proteins play an important role in many cell functions. Recent studies demonstrated persistent activation of STATs and loss of their natural inhibitors SOCS and PIAS in various human cancers. There is also evidence that experimental pharmacologic or genetic modulation of their function mignt by a new approach in anticancer treatment. The aim of this study was in vitro assesment and analysis of expression of STATs, SOCS and PIAS in glioblastoma cell lines undergoing treatment by PPARgamma agonists/antagonists because PPARgamma and STATs are tightly regulated by an overlapping set of nuclear regulatory proteins. We further analysed immunohistochemical expression of these proteins in vivo, with its correlation to grading in various brain tumors. The results of in vitro study showed decreased expression of phosphorylated form of STAT3 and increase of its inhibitors SOCS3 and PIAS3 in glioblastoma cell lines after treatment with IC50 of PPARgamma agonist ciglitazone. In vivo study failed to reveal changes in STAT3 and SOCS3 expression in either low and high grade astrocytomas, however we detect lower expression of STAT2 in low grade astrocytomas when comparing with high grade astrocytomas and lower expression of STAT3 in ependymomas when comparing with anaplastic ones. The results showed existing relationship between STAT and PPARgamma signaling in glial tumors and further suppport expected important role of STATs in regulation of growth and differentiation in these tumors.
- Published
- 2008
34. Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.
- Author
-
Olejarz, Wioletta, Sadowski, Karol, Szulczyk, Daniel, and Basak, Grzegorz
- Subjects
HEMATOLOGIC malignancies ,DRUG resistance in cancer cells ,CYTOKINE release syndrome ,BIOMARKERS ,DRUG target - Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy is a novel anticancer therapy using autologous or allogeneic T-cells. To date, six CAR-T therapies for specific B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphomas (NHL), and multiple myeloma (MM) have been approved by the Food and Drug Administration (FDA). Significant barriers to the effectiveness of CAR-T therapy include cytokine release syndrome (CRS), neurotoxicity in the case of Allogeneic Stem Cell Transplantation (Allo-SCT) graft-versus-host-disease (GVHD), antigen escape, modest antitumor activity, restricted trafficking, limited persistence, the immunosuppressive microenvironment, and senescence and exhaustion of CAR-Ts. Furthermore, cancer drug resistance remains a major problem in clinical practice. CAR-T therapy, in combination with checkpoint blockades and bispecific T-cell engagers (BiTEs) or other drugs, appears to be an appealing anticancer strategy. Many of these agents have shown impressive results, combining efficacy with tolerability. Biomarkers like extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor (ctDNA) and miRNAs may play an important role in toxicity, relapse assessment, and efficacy prediction, and can be implicated in clinical applications of CAR-T therapy and in establishing safe and efficacious personalized medicine. However, further research is required to fully comprehend the particular side effects of immunomodulation, to ascertain the best order and combination of this medication with conventional chemotherapy and targeted therapies, and to find reliable predictive biomarkers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Expression of mGluR5 in Pediatric Hodgkin and Non-Hodgkin lymphoma—A Comparative Analysis of Immunohistochemical and Clinical Findings Regarding the Association between Tumor and Paraneoplastic Neurological Disease.
- Author
-
Viezens, Ingeborg, Knierim, Ellen, Deubzer, Hedwig E., Hauptmann, Kathrin, Fassbender, Jessica, Morales-Gonzalez, Susanne, Kaindl, Angela M., Schuelke, Markus, and Nikolaus, Marc
- Subjects
NON-Hodgkin's lymphoma ,RESEARCH funding ,PARANEOPLASTIC syndromes ,GENE expression ,PEDIATRICS ,NEUROLOGICAL disorders ,IMMUNOHISTOCHEMISTRY ,RNA ,AUTOIMMUNE diseases ,HODGKIN'S disease ,SEQUENCE analysis - Abstract
Simple Summary: Autoantibodies against the metabotropic glutamate receptor 5 (mGluR5) have been linked to Ophelia syndrome, a combination of limbic encephalitis and Hodgkin lymphoma (HL). We studied mGluR5 expression in 57 pediatric HL and NHL by immunohistochemistry to explore the relationship between mGluR5 antibody formation and HL. All lymphoma tissues displayed mGluR5 staining, especially HL Reed–Sternberg cells. There was no staining in age-matched healthy lymph nodes, and we did not find GRM5 transcripts in RNA-sequencing data from normal lymphocytes. Lower mGluR5 levels in HL correlated with younger patients and EBV-positive tumors. Cases of paraneoplastic and neurological symptoms were found exclusively in the HL cohort. The frequent presence of mGluR5 in lymphoma tissue suggests a possible role in tumor development. This finding is in line with reports that glutamatergic signaling affects the outcome in other cancers. However, further studies in larger cohorts are needed to evaluate the impact of mGluR5 on HL severity. Autoantibodies targeting the neuronal antigen metabotropic glutamate receptor 5 (mGluR5) have been identified in patients with Ophelia syndrome, which describes a co-occurrence of paraneoplastic limbic encephalitis and Hodgkin lymphoma (HL). Little data exist regarding frequency and function of mGluR5 in HL and its potential role in causing seropositive paraneoplastic disease. We studied a representative cohort of pediatric HL and NHL patients (n = 57) using immunohistochemistry and fluorescence staining to investigate mGluR5 expression. All lymphoma tissues displayed positive mGluR5 staining, with focus on Hodgkin–Reed–Sternberg (H-RS) cells. We did not detect any mGluR5 staining in tumor-free lymph nodes, which is consistent with the absence of GRM5 transcripts in RNA-sequencing data from non-malignant B and T cells. The frequent presence in pediatric lymphoma falls in line with reports of mGluR5 expression and associated tumor progression in other malignancies. We tested for correlation with clinical features, focusing on disease progression and neurological symptoms. Low mGluR5 expression in H-RS cells correlated with young patient age (<15 years) and positive histology for EBV infection. Paraneoplastic or neurological symptoms were found exclusively in HL patients. While an impact of mGluR5 on HL severity remains possible, a prognostic value of mGluR5 expression levels requires further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Correction: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells
- Author
-
Vrzalikova, K, Ibrahim, M, Vockerodt, M, Perry, T, Margielewska, S, Lupino, L, Nagy, E, Soilleux, E, Liebelt, D, Hollows, R, Last, A, Reynolds, G, Abdullah, M, Curley, H, Care, M, Krappmann, D, Tooze, R, Allegood, J, Spiegel, S, Wei, W, Woodman, CBJ, and Murray, PG
- Subjects
3201 Cardiovascular Medicine and Haematology ,32 Biomedical and Clinical Sciences ,3211 Oncology and Carcinogenesis ,3. Good health - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
37. Deciphering molecular heterogeneity and dynamics of human hippocampal neural stem cells at different ages and injury states.
- Author
-
Junjun Yao, Shaoxing Dai, Ran Zhu, Ju Tan, Qiancheng Zhao, Yu Yin, Jiansen Sun, Xuewei Du, Longjiao Ge, Jianhua Xu, Chunli Hou, Nan Li, Jun Li, Weizhi Ji, Chuhong Zhu, Runrui Zhang, and Tianqing Li
- Published
- 2024
- Full Text
- View/download PDF
38. PIAS family in cancer: from basic mechanisms to clinical applications.
- Author
-
Xiaomeng Li, Rasul, Azhar, Sharif, Farzana, and Hassan, Mudassir
- Subjects
SMALL ubiquitin-related modifier proteins ,CLINICAL medicine ,UBIQUITIN ligases ,TRANSCRIPTION factors ,GENE expression - Abstract
Protein inhibitors of activated STATs (PIAS) are proteins for cytokine signaling that activate activator-mediated gene transcription. These proteins, as versatile cellular regulators, have been described as regulators of approximately 60 proteins. Dysregulation of PIAS is associated with inappropriate gene expression that promotes oncogenic signaling in multiple cancers. Multiple lines of evidence have revealed that PIAS family members show modulated expressions in cancer cells. Most frequently reported PIAS family members in cancer development are PIAS1 and PIAS3. SUMOylation as post-translational modifier regulates several cellular machineries. PIAS proteins as SUMO E3 ligase factor promotes SUMOylation of transcription factors tangled cancer cells for survival, proliferation, and differentiation. Attenuated PIAS-mediated SUMOylation mechanism is involved in tumorigenesis. This review article provides the PIAS/SUMO role in the modulation of transcriptional factor control, provides brief update on their antagonistic function in different cancer types with particular focus on PIAS proteins as a bonafide therapeutic target to inhibit STAT pathway in cancers, and summarizes natural activators that may have the ability to cure cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma.
- Author
-
Gergely, Lajos, Udvardy, Miklos, and Illes, Arpad
- Subjects
DIFFUSE large B-cell lymphomas ,B cells ,LYME disease ,HELICOBACTER pylori infections ,HEPATITIS C virus ,HEPATITIS B virus ,HELICOBACTER pylori ,PATHOGENIC microorganisms - Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. The disease is very heterogeneous, with distinct genetic alterations in subtypes. The WHO 2022 5th edition classification identifies several minor groups of large B-cell lymphoma where the pathogenetic role of viruses (like EBV and HHV-8) is identified. Still, most cases fall into the group of DLBCL not otherwise specified (NOS). No review focuses only on this specific lymphoma type in the literature. The pathogenesis of this entity is still not fully understood, but several viruses and bacteria may have a role in the development of the disease. The authors review critical pathogenetic events in the development of DLBCL (NOS) and summarize the data available on several pathogenetic viruses and bacteria that have a proven or may have a potential role in the development of this lymphoma type. The possible role of B-cell receptor signaling in the microenvironment is also discussed. The causative role of the Epstein–Barr virus (EBV), human herpesvirus-8 (HHV-8), Hepatitis C virus (HCV), human immunodeficiency virus (HIV), Hepatitis B virus (HBV), and other viruses are explored. Bacterial infections, such as Helicobacter pylori, Campylobacter jejuni, Chlamydia psittaci, Borrelia burgdorferi, and other bacteria, are also reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management.
- Author
-
Kitsou K, Kokkotis G, Rivera-Nieves J, and Bamias G
- Subjects
- Humans, Oxadiazoles therapeutic use, Oxadiazoles pharmacology, Sphingosine 1 Phosphate Receptor Modulators therapeutic use, Sphingosine 1 Phosphate Receptor Modulators pharmacology, Sphingosine-1-Phosphate Receptors metabolism, Sphingosine-1-Phosphate Receptors antagonists & inhibitors, Animals, Signal Transduction drug effects, Indans, Lysophospholipids metabolism, Sphingosine analogs & derivatives, Sphingosine metabolism, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases metabolism
- Abstract
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC) are chronic immune-mediated diseases which primarily target the intestines. In recent years, the development and regulatory approval of various immunotherapies, both biological agents and small molecules, that target specific pathways of the IBD-associated inflammatory cascade have revolutionized the treatment of IBD. Small molecules offer the advantages of oral administration and short wash-out times. Sphingosine-1-phosphate (S1P) is a bioactive metabolite of ceramide, which exerts its functions after binding to five G-protein-coupled receptors (S1PR1-S1PR5). Concerning IBD, S1P participates in the egress of lymphocytes from the secondary lymphoid tissue and their re-circulation to sites of inflammation, mainly through S1PR1 binding. In addition, this system facilitates the differentiation of T-helper cells towards proinflammatory immunophenotypes. Recently, S1P modulators have offered a valuable addition to the IBD treatment armamentarium. They exert their anti-inflammatory function via sequestration of T cell subsets in the lymphoid tissues and prevention of gut homing. In this review, we revisit the role of the S1P/S1PR axis in the pathogenesis of IBD and discuss efficacy and safety data from clinical trials and real-world reports on the two S1PR modulators, ozanimod and etrasimod, that are currently approved for IBD treatment, and comment on their potential positioning in the IBD day-to-day management. We also present recent data on emerging S1P modulators. Finally, based on the successes and failures of S1PR modulators in IBD, we discuss future avenues of IBD treatments targeting the S1P/S1PR axis., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
41. Non-invasive detection of lymphoma with circulating tumor DNA features and protein tumor markers.
- Author
-
Yu Chang, Shiyong Li, Zhiming Li, Xinhua Wang, Fangyuan Chang, Shuaipeng Geng, Dandan Zhu, Guolin Zhong, Wei Wu, Yinyin Chang, Shichun Tu, and Mao Mao
- Abstract
Background: According to GLOBOCAN 2020, lymphoma ranked as the 9
th most common cancer and the 12th leading cause of cancer-related deaths worldwide. Traditional diagnostic methods rely on the invasive excisional lymph node biopsy, which is an invasive approach with some limitations. Most lymphoma patients are diagnosed at an advanced stage since they are asymptomatic at the beginning, which has significantly impacted treatment efficacy and prognosis of the disease. Method: This study assessed the performance and utility of a newly developed blood-based assay (SeekInCare) for lymphoma early detection. SeekInCare utilized protein tumor markers and a comprehensive set of cancer-associated genomic features, including copy number aberration (CNA), fragment size (FS), end motif, and lymphoma-related virus, which were profiled by shallow WGS of cfDNA. Results: Protein marker CA125 could be used for lymphoma detection independent of gender, and the sensitivity was 27.8% at specificity of 98.0%. After integrating these multi-dimensional features, 77.8% sensitivity was achieved at specificity of 98.0%, while its NPV and PPV were both more than 92% for lymphoma detection. The sensitivity of early-stage (I-II) lymphoma was up to 51.3% (47.4% and 55.0% for stage I and II respectively). After 2 cycles of treatment, the molecular response of SeekInCare was correlated with the clinical outcome. Conclusion: In summary, a blood-based assay can be an alternative to detect lymphoma with adequate performance. This approach becomes particularly valuable in cases where obtaining tissue biopsy is difficult to obtain or inconclusive. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
42. EBV + B cell-derived exosomes promote EBV-associated T/NK-cell lymphoproliferative disease immune evasion by STAT3/IL-10/PD-L1 pathway.
- Author
-
Chen W, Xie Y, Li F, Wen P, and Wang L
- Abstract
EBV-associated T/NK-cell lymphoproliferative diseases (EBV-T/NK-LPDs) are characterized by the clonal proliferation of EBV-positive ( +) T/NK cells. EBV is typically latent in B cells and the mechanism by which the EBV genome invades T/NK cells remains unknown. Recent studies have demonstrated that exosomes derived from EBV + B cells play a pivotal role in immunosuppressive microenvironment remodeling. Moreover, the existence of an immunosuppressive microenvironment is known to be critical in the development of EBV-T/NK-LPDs. Hence, we hypothesized that exosomes derived from EBV + B cells might promote the development of EBV-T/NK-LPDs by stimulating immune evasion. In this study, we utilized paraffin sections to clarify the STAT3/IL-10/PD-L1-associated immunosuppressive microenvironment in EBV-T/NK-LPDs. Further, we extracted exosomes from BL2009 (EBV + B cell lymphoma) and CA46 (EBV- B cell lymphoma) cell lines to co-culture with cutaneous T-cell lymphoma (CTCL) cell lines, to verify the changes in the above immune evasion pathway. The paraffin sections of EBV-T/NK-LPDs showed high-expression levels of IL-10/PD-L1, which might be related to the phosphorylation of STAT3. Exosomes derived from EBV + B cells could significantly activate the STAT3/IL-10/PD-L1 pathway. After being treated with C188-9, EBV + B cell-derived exosomes were no longer able to stimulate the expression of IL-10/PD-L1 in CTCL cells. EBV-T/NK-LPDs have a STAT3/IL-10/PD-L1 overactivation-associated immunosuppressive microenvironment. Our study elucidated part of this mechanism. Exosomes derived from EBV + B could induce phosphorylation of STAT3 in CTCL cells, leading to the overexpression of IL-10/PD-L1. Our findings might shed light on new directions for understanding immune evasion in EBV-T/NK-LPDs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
43. Epstein–Barr Virus Driven Hodgkin's Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma.
- Author
-
Mohammadi-Oroujeh, Moeen, Mehreen, Ansa, and Grinblatt, David L.
- Subjects
HODGKIN'S disease ,MULTIPLE myeloma ,EPSTEIN-Barr virus ,DARATUMUMAB ,CANCER treatment - Abstract
In this case, we describe the potential risk of developing an infectious complication leading to a secondary malignancy after a short course of immunotherapy. We report a patient who presented with Epstein–Barr virus (EBV) driven Hodgkin's lymphoma after treatment with a short course of daratumumab along with pomalidomide and dexamethasone for relapsed multiple myeloma. Although there have been limited documented cases of daratumumab treatment leading to EBV reactivation, in patients presenting with infectious symptoms or neutropenia on a daratumumab-based regimen, testing for EBV should not be overlooked. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. A Mouse Model to Study the Pathogenesis of γ-herpesviral Infections in Germinal Center B Cells.
- Author
-
Rambold, Ursula, Sperling, Stefanie, Chew, Zakir, Wang, Yan, Steer, Beatrix, Zeller, Krisztina, Strobl, Lothar J., Zimber-Strobl, Ursula, and Adler, Heiko
- Subjects
B cells ,GERMINAL centers ,LABORATORY mice ,ANIMAL disease models ,EPSTEIN-Barr virus ,PATHOGENESIS - Abstract
CD30-positive germinal center (GC)-derived B cell lymphomas are frequently linked to Epstein–Barr Virus (EBV) infection. However, a suitable animal model for the investigation of the interplay between γ-herpesvirus and host cells in B cell pathogenesis is currently lacking. Here, we present a novel in vivo model enabling the analysis of genetically modified viruses in combination with genetically modified GC B cells. As a murine γ-herpesvirus, we used MHV-68 closely mirroring the biology of EBV. Our key finding was that Cre-mediated recombination can be successfully induced by an MHV-68 infection in GC B cells from Cγ1-Cre mice allowing for deletion or activation of loxP-flanked cellular genes. The implementation of PrimeFlow RNA assay for MHV-68 demonstrated the enrichment of MHV-68 in GC and isotype-switched B cells. As illustrations of virus and cellular modifications, we inserted the EBV gene LMP2A into the MHV-68 genome and induced constitutively active CD30-signaling in GC B cells through MHV-68 infections, respectively. While the LMP2A-expressing MHV-68 behaved similarly to wildtype MHV-68, virally induced constitutively active CD30-signaling in GC B cells led to the expansion of a pre-plasmablastic population. The findings underscore the potential of our novel tools to address crucial questions about the interaction between herpesviral infections and deregulated cellular gene-expression in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. The Eradication of Carcinogenic Viruses in Established Solid Cancers.
- Author
-
Elkoshi, Zeev
- Subjects
RETROVIRUSES ,T cells ,REGULATORY T cells ,IMMUNOREGULATION ,CANCER prognosis - Abstract
Carcinogenic viruses (oncoviruses) can initiate cancer, but their impact on established cancer varies. Some of these viruses prolong survival while others shorten it. This study classifies oncoviruses into two categories: viruses which induce a strong CD8+T cell reaction in non-cancerous tissues, and viruses which induce a weak CD8+ T cell reaction in non-cancerous tissues. The classification proves useful in predicting the effect of oncoviruses on the prognosis of solid cancers. Therefore, while eliminating carcinogenic viruses in healthy individuals (for example by immunization) may be important for cancer prevention, this study suggests that only viruses which induce a weak CD8+ T cell reaction should be eradicated in established solid tumors. The model correctly predicts the effect of oncoviruses on survival for six out of seven known oncoviruses, indicating that immune modulation by oncoviruses has a prominent effect on prognosis. It seems that CD8+ T cell response to oncoviruses observed in infected benign tissues is retained in infected tumors. Clinical significance: the effect of oncoviruses on solid cancer prognosis can be predicted with confidence based on immunological responses when clinical data are unavailable. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. The Role of Viral Infection in the Pathogenesis of Interstitial Cystitis/Bladder Pain Syndrome.
- Author
-
Jhang, Jia-Fong and Kuo, Hann-Chorng
- Abstract
Purpose of Review: The pathogenesis of interstitial cystitis/bladder pain syndrome (IC/BPS) is still unclear. The diagnosis of IC/BPS is made after ruling out bacterial cystitis. However, viral infection in the bladder might be a pathogenic factor for IC/BPS. The purpose of this review is to demonstrate the association between viral infection and IC/BPS. Recent Findings: The presence of urinary tract viruses in patients with IC/BPS has been sporadically investigated since the 1970s. Early studies used viral culture to investigate urine and bladder tissue samples from patients with IC/BPS, but viruses were rarely detected. With polymerase chain reaction, several studies have reported increased papillomavirus, BK virus, and John Cunningham virus viral load in urine samples from patients with IC/BPS. The presence of urinary papillomavirus was associated with more severe IC/BPS symptoms. Recent studies have used transcriptomic RNA sequencing to investigate gene expression in bladder tissue samples from patients with IC/BPS. Enriched viral infection-associated gene pathways in patients with IC/BPS were noted in the studies, including cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, human papillomavirus infection, and Epstein–Barr virus (EBV) infection. Our recent studies reported the presence of EBV in IC/BPS bladders, especially in patients with IC/BPS with Hunner's lesion (HIC). EBV latency and lytic infection were observed in HIC bladders, indicating EBV infection persistence and reactivation. EBV latency infection in B cells could induce brain-derived neurotrophic factor overexpression and might cause nerve hyperplasia in IC/BPS bladders. Summary: The presence of urinary virus in the patients with IC/BPS suggested that viral infection might be a pathogenic factor in patients with IC/BPS. Molecular evidence from IC/BPS bladder tissue also showed that viral infection may involve the pathogenesis of IC/BPS. Further studies are needed to clarify the mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. Non-Response of Epstein–Barr Virus-Associated Breast Cancer after Primary Chemotherapy: Report of Two Cases.
- Author
-
Gutjahr, Ewgenija, Fremd, Carlo, Arnscheidt, Johanna, Penzel, Roland, Wacker, Jürgen, and Sinn, Peter
- Subjects
EPSTEIN-Barr virus ,TRIPLE-negative breast cancer ,BREAST cancer ,CANCER invasiveness ,IN situ hybridization ,CANCER chemotherapy - Abstract
Based on epidemiological evidence and molecular findings, a possible association of Epstein–Barr virus (EBV) with the carcinogenesis of breast cancer has been described. However, the frequency of EBV in breast cancer and the role of EBV regarding tumor progression or therapeutic results is largely unexplored. Here, we report on two cases of advanced, lymph node-positive invasive breast cancer of no special type (NST), histologically showing no clinical or histological evidence of tumor regression as an equivalent of a lack of response to primary systemic therapy. Both tumors were considered to be EBV-associated due to their positivity in EBV-encoded RNA (EBER) in situ hybridization (ISH) and their immunoreactivity against EBV Epstein–Barr nuclear antigen 1 (EBNA1). We hypothesize that the unusual non-response to chemotherapy in these cases of breast cancer classified as triple-negative and HER2-positive may be linked to the EBV co-infection of tumor cells. Therefore, EBV tumor testing should be considered in patients with breast cancer presenting with resistance to chemotherapy. This hypothesis may provide a new aspect in the context of EBV-associated mechanisms of tumor progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Potential Associations between Vascular Biology and Hodgkin's Lymphoma: An Overview.
- Author
-
Rodrigues, Wellington Francisco, Miguel, Camila Botelho, Abreu, Melissa Carvalho Martins de, Neto, Jamil Miguel, and Oliveira, Carlo José Freire
- Subjects
HODGKIN'S disease ,CYTOKINES ,INTERLEUKINS ,CELL culture ,GROWTH factors ,NF-kappa B ,CELLULAR signal transduction ,MAJOR histocompatibility complex ,TUMOR necrosis factors ,CELL adhesion molecules ,CYTOLOGY ,CHEMOKINES ,GENE amplification ,BRAIN-derived neurotrophic factor ,PLATELET-derived growth factor ,BLOOD - Abstract
Simple Summary: Hodgkin's lymphoma is a type of cancer that affects the lymphatic system, which is an important part of the body's immune system. This type of cancer involves a set of molecules and cells that promote tumor survival. Some structures found in the tumor niche are associated with vascular biology, which integrates a network of molecules and cells that play a fundamental role in nutrition and oxygen supply to tissues, including tumors. Thus, the main objective of this study was to improve our knowledge of the relationship between vascular biology and Hodgkin's lymphoma and to enable new studies on disease intervention. Here, we describe the main cells and molecules associated with tumors that play a role in vascular biology. Additionally, this study addresses the main models of disease experimentation. Hodgkin's lymphoma (HL) is a lymphatic neoplasm typically found in the cervical lymph nodes. The disease is multifactorial, and in recent years, the relationships between various vascular molecules have been explored in the field of vascular biology. The connection between vascular biology and HL is intricate and the roles of several pathways remain unclear. This review summarizes the cellular and molecular relationships between vascular biology and HL. Proteins associated with various functions in vascular biology, including cytokines (TNF-α, IL-1, IL-13, and IL-21), chemokines (CXCL10, CXCL12, and CCL21), adhesion molecules (ELAM-1/VCAM-1), and growth factors (BDNF/NT-3, platelet-derived growth factor receptor-α), have been linked to tumor activity. Notable tumor activities include the induction of paracrine activation of NF-kB-dependent pathways, upregulation of adhesion molecule regulation, genome amplification, and effective loss of antigen presentation mediated by MHC-II. Preclinical study models, primarily those using cell culture, have been optimized for HL. Animal models, particularly mice, are also used as alternatives to complex biological systems, with studies primarily focusing on the physiopathogenic evaluation of the disease. These biomolecules warrant further study because they may shed light on obscure pathways and serve as targets for prevention and/or treatment interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma.
- Author
-
Martynchyk, Arina, Chowdhury, Rakin, Hawkes, Eliza A., and Keane, Colm
- Subjects
THERAPEUTIC use of monoclonal antibodies ,HODGKIN'S disease ,PROGRAMMED cell death 1 receptors ,SEQUENCE analysis ,CANCER relapse ,MACROPHAGES ,MOLECULAR biology ,TUMOR markers ,HISTOLOGY ,T cells ,DISEASE risk factors - Abstract
Simple Summary: Approximately one in seven patients with classical Hodgkin lymphoma have refractory disease or relapse after standard front line chemotherapy. Prognostic biomarkers could help determine candidates for more effective treatment. The latest advances in research techniques have contributed to new insights in understanding the tumour microenvironment of Hodgkin lymphoma and the crucial role it plays in the disease course and response to treatment. Many new potential biomarkers are being explored in this setting and the results of these studies, as well as diagnostic methodologies, are presented in this review. Classical Hodgkin lymphoma (cHL) accounts for 0.4% of all new cancer cases globally. Despite high cure rates with standard treatment, approximately 15% of patients still experience relapsed or refractory (RR) disease, and many of these eventually die from lymphoma-related causes. Exciting new targeted agents such as anti-PD-1 agents and brentuximab vedotin have changed the therapeutic paradigm beyond chemotherapy and radiotherapy alone. Advances in understanding of the molecular biology are providing insights in the context of novel therapies. The signature histology of cHL requires the presence of scant malignant Hodgkin Reed–Sternberg cells (HRSCs) surrounded by a complex immune-rich tumour microenvironment (TME). The TME cellular composition strongly influences outcomes, yet knowledge of the precise characteristics of TME cells and their interactions with HRSCs is evolving. Novel high-throughput technologies and single-cell sequencing allow deeper analyses of the TME and mechanisms elicited by HRSCs to propagate growth and avoid immune response. In this review, we explore the evolution of knowledge on the prognostic role of immune cells within the TME and provide an up-to-date overview of emerging prognostic data on cHL from new technologies that are starting to unwind the complexity of the cHL TME and provide translational insights into how to improve therapy in the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. Lymphomas with plasmablastic features: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
- Author
-
Dotlic, Snjezana, Gibson, Sarah E., Hartmann, Sylvia, Hsi, Eric D., Klimkowska, Monika, Rodriguez-Pinilla, Socorro Maria, Sabattini, Elena, Tousseyn, Thomas A., de Jong, Daphne, and Dojcinov, Stefan
- Abstract
Lymphomas with plasmablastic features are a heterogeneous group of aggressive and mostly uncommon neoplasms of varied aetiologies, presenting in immunocompetent individuals as well as in immunodeficiency, associated with EBV and Kaposi sarcoma virus infections, and some as progression from indolent B-cell lymphomas. They show overlapping diagnostic features and pose a differential diagnosis with other aggressive B-cell lymphomas that can downregulate the B-cell expression programme. The spectrum of rare reactive proliferations and all lymphomas defined by plasmablastic features, together with an expanding range of poorly characterised, uncommon conditions at the interface between reactive lymphoid proliferations and neoplasia submitted to the session V of the 20
th European Association for Haematopathology/Society for Hematopathology lymphoma workshop are summarised and discussed in this paper. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.